Preferred Label : Erlotinib Hydrochloride;
MeSH definition : A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE
INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL
CELL LUNG CANCER.;
MeSH synonym : Hydrochloride, Erlotinib; Erlotinib HCl; HCl, Erlotinib;
MeSH Hyperonym : erlotinib; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;
MeSH hyponym : tarceva; OSI-774; 11C-erlotinib; CP 358774; OSI 774; OSI774; 358774, CP; CP 358,774; 358,774, CP; CP-358,774; CP358,774; CP-358774; CP358774; 11C erlotinib;
MeSH Related Number : 183319-69-9; J4T82NDH7E; DA87705X9K;
Is substance : O;
UNII : DA87705X9K;
Origin ID : D000069347;
UMLS CUI : C1533491;
ATC code(s)
- Allowable qualifiers
- CISMeF manual mappings
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to NTBT
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE
INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL
CELL LUNG CANCER.
https://www.has-sante.fr/portail/jcms/c_2892930/fr/tarceva
https://www.has-sante.fr/portail/jcms/c_2892930/fr/tarceva-erlotinib-inhibiteur-de-tyrosine-kinase
2018
false
France
French
evaluation of the transparency committee
Erlotinib Hydrochloride
guidelines for drug use
Tyrosine Kinase Inhibitors
insurance, health, reimbursement
administration, oral
erlotinib
protein kinase inhibitors
neoplasm metastasis
carcinoma, non-small-cell lung
mutation
treatment outcome
ErbB Receptors
ErbB Receptors
---
http://conseil-scientifique.public.lu/fr/publications/oncologie/erlotinib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
guidelines for drug use
Erlotinib Hydrochloride
erlotinib
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
neoplasm metastasis
Locally Advanced Malignant Neoplasm
disease progression
Activating EGFR Gene Mutation
mutation
carcinoma, non-small-cell lung
antineoplastic combined chemotherapy protocols
survival analysis
Metastatic Malignant Neoplasm in the Pancreas
Tyrosine Kinase Inhibitors
ErbB Receptors
---
TARCEVA (erlotinib) - Use in Maintenance Treatment for Patients
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/56720a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Maintenance Therapy
risk assessment
carcinoma, non-small-cell lung
neoplasm metastasis
Locally Advanced Malignant Neoplasm
carcinoma, non-small-cell lung
erlotinib
drug evaluation
Activating EGFR Gene Mutation
treatment outcome
Erlotinib Hydrochloride
ErbB Receptors
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-EGFR-erlotinib-gefitinib-afatinib
2016
false
false
false
France
French
guidelines for drug use
patients guideline
practice guideline
antineoplastic agents
antineoplastic agents
antineoplastic agents
administration, oral
Erlotinib Hydrochloride
Erlotinib Hydrochloride
Erlotinib Hydrochloride
erlotinib
protein kinase inhibitors
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
continuity of patient care
drug monitoring
drug interactions
pregnancy
carcinoma, non-small-cell lung
interdisciplinary communication
afatinib
afatinib
afatinib
afatinib
gefitinib
Tyrosine Kinase Inhibitors
quinazolines
quinazolines
quinazolines
ErbB Receptors
Gefitinib
Gefitinib
Gefitinib
Afatinib
Afatinib
Afatinib
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/942
2014
false
Canada
French
lung neoplasms
carcinoma, non-small-cell lung
journal article
lung neoplasms
carcinoma, non-small-cell lung
lung neoplasms
carcinoma, non-small-cell lung
antineoplastic agents
antibodies, monoclonal, humanized
angiogenesis inhibitors
protein kinase inhibitors
pyrazoles
pyridines
Erlotinib Hydrochloride
Pemetrexed
Bevacizumab
Gefitinib
Crizotinib
---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/903
2013
false
Canada
French
antibiotic therapy
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
journal article
exanthema
minocycline
exanthema
carcinoma, non-small-cell lung
minocycline
minocycline
erlotinib
protein kinase inhibitors
anti-bacterial agents
anti-bacterial agents
ErbB Receptors
---
http://www.has-sante.fr/portail/jcms/c_1260373/tarceva
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/tarceva_06062012_avis_ct12040.pdf
2012
false
France
French
evaluation of the transparency committee
Erlotinib Hydrochloride
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
insurance, health, reimbursement
administration, oral
erlotinib
protein kinase inhibitors
protein kinase inhibitors
neoplasm metastasis
carcinoma, non-small-cell lung
mutation
treatment outcome
clinical trials, phase iii as topic
randomized controlled trials as topic
disease-free survival
ErbB Receptors
ErbB Receptors
---
https://www.ema.europa.eu/medicines/human/EPAR/Tarceva
2012
false
United Kingdom
French
English
syndication feed
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
treatment outcome
drug evaluation
protein kinase inhibitors
carcinoma, non-small-cell lung
erlotinib
administration, oral
pancreatic neoplasms
neoplasm metastasis
drug evaluation
summary of product characteristics
package leaflet
ErbB Receptors
---
http://www.has-sante.fr/portail/jcms/c_1320038/tarceva-erlotinib-inhibiteur-de-la-tyrosine-kinase
http://www.has-sante.fr/portail/jcms/c_1319567/tarceva-06062012-synthese
http://www.has-sante.fr/portail/jcms/c_1262716/tarceva-06062012-avis-ct12040
2012
false
France
French
Erlotinib Hydrochloride
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
carcinoma, non-small-cell lung
neoplasm metastasis
guidelines for drug use
evaluation of the transparency committee
mutation
administration, oral
protein kinase inhibitors
protein kinase inhibitors
erlotinib
treatment outcome
clinical trials, phase iii as topic
randomized controlled trials as topic
Progression-Free survival
disease-free survival
survival analysis
ErbB Receptors
ErbB Receptors
---
http://www.has-sante.fr/portail/jcms/c_1070973/tarceva
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-07/tarceva_-_ct-10255.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/tarceva_ct_10255.pdf
2011
false
France
French
English
evaluation of the transparency committee
Erlotinib Hydrochloride
maintenance chemotherapy
protein kinase inhibitors
administration, oral
carcinoma, non-small-cell lung
treatment outcome
insurance, health, reimbursement
neoplasm metastasis
survival analysis
erlotinib
---
http://www.has-sante.fr/portail/jcms/c_1172150/tarceva-erlotinib-inhibiteur-de-la-tyrosine-kinase
2011
false
France
French
Erlotinib Hydrochloride
treatment outcome
randomized controlled trials as topic
disease-free survival
maintenance chemotherapy
administration, oral
protein kinase inhibitors
erlotinib
insurance, health, reimbursement
carcinoma, non-small-cell lung
guidelines for drug use
pharmacovigilance note
---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/ProjetPilote_Cancer/Document_synthese_final_CAV.pdf
2011
false
Canada
French
Pemetrexed
Erlotinib Hydrochloride
Everolimus
drug evaluation
drug evaluation
antineoplastic agents
Cost-Benefit analysis
treatment outcome
insurance, health, reimbursement
carcinoma, renal cell
neoplasm metastasis
pemetrexed
lung neoplasms
canada
gefitinib
everolimus
erlotinib
survival analysis
technical report
drug information
Gefitinib
---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/14060a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/14580a-fra.php
2009
false
Canada
French
English
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
protein kinase inhibitors
intestinal perforation
stevens-johnson syndrome
corneal diseases
pharmacovigilance note
ErbB Receptors
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-5077_tarceva_.pdf
http://www.has-sante.fr/portail/jcms/c_400947/tarceva
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/tarceva_ct_5077.pdf
http://www.has-sante.fr/portail/jcms/c_657256/tarceva
2008
false
France
French
evaluation of the transparency committee
Erlotinib Hydrochloride
administration, oral
protein kinase inhibitors
erlotinib
antineoplastic combined chemotherapy protocols
pancreatic neoplasms
neoplasm metastasis
insurance, health, reimbursement
carcinoma, non-small-cell lung
treatment outcome
survival analysis
---
http://www.meddispar.fr/medicaments/3692352
2008
false
France
French
Erlotinib Hydrochloride
administration, oral
tablets
drug monitoring
continuity of patient care
drug prescriptions
legislation, drug
erlotinib
drug information
---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/14521a-fra.php
2008
false
Canada
French
English
Erlotinib Hydrochloride
Tyrosine Kinase Inhibitors
lung neoplasms
Drug-Related side effects and adverse reactions
hepatorenal syndrome
hepatic insufficiency
canada
protein kinase inhibitors
pharmacovigilance note
ErbB Receptors
---
http://www.meddispar.fr/medicaments/3692346
2008
false
France
French
Erlotinib Hydrochloride
tablets
drug monitoring
administration, oral
continuity of patient care
drug prescriptions
legislation, drug
erlotinib
drug information
---
http://www.omedit-centre.fr/portail/gallery_files/site/136/2953/5062/5139.pdf
2007
false
France
French
Erlotinib Hydrochloride
Cetuximab
drug eruptions
skin diseases
skin diseases
antineoplastic agents
protein kinase inhibitors
drug eruptions
practice guideline
---
http://www.meddispar.fr/medicaments/3692323
2007
false
France
French
Erlotinib Hydrochloride
continuity of patient care
drug prescriptions
legislation, drug
erlotinib
erlotinib hydrochloride
drug information
---
http://www.msss.gouv.qc.ca/sujets/organisation/lutte-contre-le-cancer/documents/guides-cepo-pdf/CEPO-Tarceva_et_poumon_(2005-06).pdf
2005
false
false
Canada
French
English
Erlotinib Hydrochloride
protein kinase inhibitors
lung neoplasms
carcinoma, non-small-cell lung
lung neoplasms
carcinoma, non-small-cell lung
survival rate
lung neoplasms
carcinoma, non-small-cell lung
bibliography of medicine
Evidence-Based medicine
quebec
Tyrosine Kinase Inhibitors
erlotinib
graph
guidelines for drug use
ErbB Receptors
---
